Edited by Dentaltown staff
CAPUA, Italy—Pierrel Pharma recently received recognition from the Edison Awards, an organization known for acknowledging innovation, creativity, and ingenuity in the global economy, for its early oral cancer screening device: Goccles. The FDA-approved medical device is used in combination with traditional examination to help identify early signs of oral cancer.
The eyewear utilizes a patented optical filter with a standard curing light, exposing the fluorescence of healthy mucosa and potentially suspicious pre-cancerous and cancerous lesions. With Goccles, there is no need to purchase additional consumables.
Pierrel Pharma’s chief executive officer, Fabio Velotti, attributes the Best New Product Silver Award win to the company’s dedication to research and development, as well as its overall mission to create better dental health care experiences for professionals and patients.
“I am so proud of Goccles and how it is transforming the oral cancer screening process on the dental side. As time passes, I believe we will see a major shift in dental professionals’ attitudes towards their role in early detection of oral cancer,” he said. “Pierrel Pharma is known for developing Orabloc, a leading anesthetic product for dental procedures, which since marketed is now used by one out of every four U.S. dentists. I look forward to the day Goccles becomes a ‘household name’ in its own right among dental professionals.”
Goccles was launched in the U.S. in 2018 and is available through all major distributors, including Patterson Dental, Henry Schein, Benco Dental and Darby Dental.